Scholarlink

Background <p>Anaemia and thrombocytopenia adversely affect adolescent HIV outcomes, yet adolescent-specific data from the tenofovir/lamivudine/dolutegravir (TLD) era remain scarce, and access to full blood count (FBC) testing is limited in Cameroon. We evaluated the prevalence, severity, and factors associated with these cytopenias among adolescents living with HIV (ADLHIV) in the TLD era.</p> Methods <p>Multicentre cross-sectional study was conducted among ADLHIV (10–19 years) receiving TLD in the CIPHER-ADOLA cohort in Cameroon. Full blood count, viral load (VL) and CD4-count were performed. Factors associated with anaemia and thrombocytopenia were ascertained.</p> Results <p>A total of 252 ADLHIV was enrolled (50.8% male, 83.3% were vertically infected, and 7.2% were underweighted). ART-duration and TLD-exposure were 10 [6–13] years and 26 [12–33] months, respectively. Concerning virological response, 71.4%, 13.1%, and 15.5% had a VL &lt; 50, 50–999, and ≥ 1000, respectively. Overall, 102 (40.5%) were anaemic, with only 2.9% severe. Anaemia rate was twice higher in females (55.6%, <i>p</i> &lt; 0.001); 64.1% with VL ≥ 1000 against 35.0% with VL &lt; 50 (<i>p</i> = 0.003); 60.0% with CD4 &lt; 200 against 35.4% with CD4 &gt; 500 (<i>p</i> = 0.046). Regarding thrombocytopenia, the burden was low (6.7%), but higher among VL ≥ 1000 (<i>p</i> = 0.003). Multivariate analyses showed a threefold higher anaemia prevalence in females (aOR [95% CI: 3.406 [1.8952-5.940]), fivefold without formal education (0.191 [0.047–0.776]), threefold in VL ≥ 1000 copies/ml (0.338 [0.156–0.733]). Thrombocytopenia was fourfold more likely in males (aOR: 0.236 [0.072–0.774]) and sevenfold more likely in individuals with VL ≥ 1000 copies/mL (aOR: 0.140 [0.038–0.510]).</p> Conclusion <p>In the TLD era, anaemia remains common but generally mild, and thrombocytopenia is uncommon. Cytopenias were associated with unsuppressed viral load, with a stronger association for anaemia in females. These findings support programmatic targeted haemovigilance prioritising adolescents with unsuppressed viral load, particularly females, in settings where access to FBC testing is limited.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月8日

查看全文
  • Nadine Nguendjoung Fainguem,
  • Yagai Bouba,
  • Rachel Kamgaing,
  • Jeremiah Efakika Gabisa,
  • Aude Christelle Ka’e,
  • Michel Carlos Tommo Tchouaket,
  • Alex Durand Nka,
  • Cynthia Ayafor,
  • Lum Forgwei,
  • Nelly Kamgaing,
  • Suzie Ndiang Tetang,
  • Francis Ndongo Ateba,
  • Desire Takou,
  • Dominik Guebiapsi Tameza,
  • Félicité Noukayo,
  • Alice Ketchaji,
  • Ezechiel Ngoufack Jagni Semengue,
  • Wome Basseck Roland,
  • Wiadamong Agabus,
  • Abdou Rahamani Gnambi,
  • Catherine Eyenga,
  • Naomi Karell Etame,
  • Aurelie Minelle Kengni Ngueko,
  • Larissa Gaëlle Moko Fotso,
  • Junie Flore Yimga,
  • Krystel Nomo Zam,
  • Annie Nga Motaze,
  • Collins Ambe Chenwi,
  • Grace Anong Beloumou,
  • Sandrine Claire Djupsa Njdeyep,
  • Upal Roy,
  • Rogers Awoh Ajeh,
  • Anne Esther Njom Nlend,
  • Paul Ndombo Koki,
  • Hyppolite Kuekou Tchidjou,
  • Daniele Armenia,
  • Maria Mercedes Santoro,
  • Francesca Ceccherini-Silberstein,
  • Samuel Martin Sosso,
  • Alexis Ndjolo,
  • Vittorio Colizzi,
  • Carlo-Federico Perno,
  • Joseph Fokam

摘要

Background

Anaemia and thrombocytopenia adversely affect adolescent HIV outcomes, yet adolescent-specific data from the tenofovir/lamivudine/dolutegravir (TLD) era remain scarce, and access to full blood count (FBC) testing is limited in Cameroon. We evaluated the prevalence, severity, and factors associated with these cytopenias among adolescents living with HIV (ADLHIV) in the TLD era.

Methods

Multicentre cross-sectional study was conducted among ADLHIV (10–19 years) receiving TLD in the CIPHER-ADOLA cohort in Cameroon. Full blood count, viral load (VL) and CD4-count were performed. Factors associated with anaemia and thrombocytopenia were ascertained.

Results

A total of 252 ADLHIV was enrolled (50.8% male, 83.3% were vertically infected, and 7.2% were underweighted). ART-duration and TLD-exposure were 10 [6–13] years and 26 [12–33] months, respectively. Concerning virological response, 71.4%, 13.1%, and 15.5% had a VL < 50, 50–999, and ≥ 1000, respectively. Overall, 102 (40.5%) were anaemic, with only 2.9% severe. Anaemia rate was twice higher in females (55.6%, p < 0.001); 64.1% with VL ≥ 1000 against 35.0% with VL < 50 (p = 0.003); 60.0% with CD4 < 200 against 35.4% with CD4 > 500 (p = 0.046). Regarding thrombocytopenia, the burden was low (6.7%), but higher among VL ≥ 1000 (p = 0.003). Multivariate analyses showed a threefold higher anaemia prevalence in females (aOR [95% CI: 3.406 [1.8952-5.940]), fivefold without formal education (0.191 [0.047–0.776]), threefold in VL ≥ 1000 copies/ml (0.338 [0.156–0.733]). Thrombocytopenia was fourfold more likely in males (aOR: 0.236 [0.072–0.774]) and sevenfold more likely in individuals with VL ≥ 1000 copies/mL (aOR: 0.140 [0.038–0.510]).

Conclusion

In the TLD era, anaemia remains common but generally mild, and thrombocytopenia is uncommon. Cytopenias were associated with unsuppressed viral load, with a stronger association for anaemia in females. These findings support programmatic targeted haemovigilance prioritising adolescents with unsuppressed viral load, particularly females, in settings where access to FBC testing is limited.